Periprostatic fat magnetic resonance imaging based radiomics nomogram for predicting biochemical recurrence-free survival in patients with non-metastatic prostate cancer after radical prostatectomy

Abstract

Abstract Objective To build and validate a periprostatic fat magnetic resonance imaging (MRI) based radiomics nomogram for prediction of biochemical recurrence-free survival (bRFS) of patients with non-metastatic prostate cancer (PCa) receiving radical prostatectomy (RP). Methods A retrospective study was conducted on 356 patients with non-metastatic PCa who underwent preoperative mpMRI followed by RP treatment at our institution. Radiomic features were extracted from both intratumoral region and the periprostatic fat region, which were segmented on images obtained through T2-weighted imaging (T2WI) and apparent-diffusion coefficient (ADC) imaging. Three radiomics models were developed by applying the Least absolute shrinkage and selection operator (LASSO) Cox regression, followed by Cox risk regression to construct a combined radiomics-clinical model by integrating the optimal radiomics score and clinicopathological risk factors to draw a nomogram. The predictive performance was evaluated using receiver operating characteristic (ROC) curves, Kaplan-Meier analysis and calibration curves. Results One hundred and twenty-one patients (33.98%) experienced biochemical recurrence. ROC analyses showed that the Area Under the Curve (AUC) of the periprostatic fat-intratumoral radiomics model demonstrated the highest AUC at 0.921 (95%CI, 0.857–0.981), 0.875 (95%CI, 0.763–0.950), 0.854 (95%CI, 0.706–0.923) for 1-year, 3-years and 5-years bRFS. Multivariate Cox regression analysis revealed that Pathological T stage, ISUP grading group and Positive surgical margin were independent prognostic factors for predicting bRFS. A radiomics-clinical nomogram based on these clinical predictors and periprostatic fat-intratumoral radiomics score was constructed. Kaplan-Meier analyses showed that radiomics-clinical nomogram was significantly related with survival of PCa (P < 0.001); and calibration curves revealed the predicted and observed survival probability of 1-year, 3-year and 5-year bRFS had high degree of consistency in the training and validation group. The radiomics-clinical nomogram showed a significant improvement than the clinical model for 1-year (AUC, 0.944; 95%CI, 0.912–0.990 vs. AUC, 0.839; 95%CI, 0.661–0.928; P = 0.009), 3-year (AUC, 0.864; 95%CI, 0.772–0.969 vs. AUC, 0.776; 95%CI, 0.602–0.872; P = 0.008), and 5-year bRFS (AUC, 0.907; 95%CI, 0.836–0.982 vs. AUC, 0.819; 95%CI, 0.687–0.915; P = 0.027). Conclusions This study developed and validated the radiomics-clinical nomogram for the prediction of bRFS in non-metastatic PCa patients underwent RP.

Keywords

• Prostate cancer
• Radiomics
• Periprostatic fat
• Biochemical recurrence-free survival
• Nomogram